Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cedars-sinai Medical Center
Headquarters: Los Angeles, CA, United States of America
Website: http://cedars-sinai.edu
Year Founded: 1902
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Feb 29, 2024
Discovery & Translation
Science spotlight: SOX9 switch for kidney regeneration, improved base editors and more
BioCentury’s roundup of translational innovations
BioCentury | Sep 14, 2023
Regulation
FDA to weigh how broadly to expand label for Alnylam’s Onpattro
FDA panel votes 9-3 that the benefits of Onpattro to treat ATTR cardiomyopathy outweigh risks
BioCentury | Apr 17, 2023
Deals
Merck enters precision immunology via $10.8B Prometheus takeout
December readouts in ulcerative colitis and Crohn’s disease drove up stock price, leading to $200-per-share deal
BioCentury | Dec 1, 2021
Discovery & Translation
Two applications of omics-based biomarkers in cancer; plus Evox, Akoya and more
BioCentury’s roundup of translational news
BioCentury | Apr 14, 2021
Management Tracks
Management shuffle at Novavax; plus Skyhawk, Kyverna, Gemini and more
Greg Covino will step down as CFO and become executive adviser to Novavax Inc. (NASDAQ:NVAX). The vaccine developer hired Troy Morgan as SVP and chief compliance officer and promoted Gale Smith to SVP
BioCentury | Dec 5, 2020
Product Development
Dec. 4 Quick Takes: Zogenix in Dravet deal with start-up; plus updates from BioCryst, Takeda, AB Science, Sutro, Lilly, Cedars-Sinai
Aiming to reverse Dravet, Tevard partners with ZogenixZogenix Inc. (NASDAQ:ZGNX) will collaborate with Tevard Biosciences to develop transfer RNA-based gene therapies to treat Dravet syndrome and
BioCentury | May 26, 2020
Distillery Therapeutics
Disrupting mitochondrial DNA-mediated paracrine signaling for prostate cancer
BioCentury | Jun 19, 2019
Distillery Therapeutics
HAS2 and NOTCH1 identified as targets in liver fibrosis induced by hepatitis B, hepatitis C and NASH
Items per page:
1 - 10 of 115